Answering criticism with evidence
Is COPD balloon therapy controversial?
The short answer: yes, it is debated — and some of the criticism is justified. On this page we compare the criticisms with the published data and state plainly which points we accept.
Last updated: 28 September 2026
Short answer
Critical assessments of COPD balloon therapy are being published. The published data confirms part of that criticism: the method does not improve lung function (FEV1), does not cure COPD and is not suitable for every patient. Even so, significant improvement was reported in breathlessness, exacerbation frequency and quality of life.
Why this page exists
The way to describe a treatment is not to ignore criticism or to attack whoever raises it. Below we take each point of criticism in turn and look at what the published data shows. Where the criticism is justified, we say so plainly. Every figure comes from a publication we link to.
Points of criticism and what the published data answers
Does this method improve lung function (FEV1)?
It does not. In the prospective study published in the Journal of Clinical Medicine, no statistically significant change in FEV1 was found at 12 months (p=0.291). Exercise capacity was unchanged in the same study as well (6-minute walk distance, p=0.420). We do not present this method as a treatment that improves lung function.
Does balloon therapy cure COPD?
It does not. The permanent lung damage in COPD cannot be reversed, and bronchoscopic interventions do not reverse it. Stopping smoking, taking medication regularly and pulmonary rehabilitation remain the foundation of treatment. Balloon dilation is an option placed alongside them in selected patients, not instead of them.
Can every COPD patient have this treatment?
No. The published study was conducted in patients with the chronic bronchitis-predominant COPD phenotype, GOLD stage II–IV and mMRC ≥ 2. In emphysema-predominant COPD, different bronchoscopic methods are considered. Only a pulmonologist can decide on eligibility.
Is there published clinical data for the method?
There is. A prospective interventional study in 35 patients with chronic bronchitis-predominant COPD was published in the Journal of Clinical Medicine (July 2026 · PMID 42513520); 25 patients completed the 12-month follow-up. The study reported significant improvement in breathlessness (mMRC, p<0.001), in the number of moderate/severe exacerbations (p=0.022) and in quality-of-life scores (SGRQ symptom, activity, impact and total, all p<0.01). This patient number does not remove the need for larger and comparative studies.
If lung function does not improve, is the improvement in symptoms meaningful?
The international GOLD report defines the two main goals of COPD treatment as reducing symptoms and lowering the risk of exacerbations. Even when the number on a lung function test does not change, less breathlessness, fewer exacerbations and better quality-of-life scores are outcomes that directly affect a patient's daily life. That is why these measures are legitimate clinical goals.
Do the publications contradict each other?
They do. A larger follow-up series of 188 patients published in Medicine (Baltimore) in November 2018 reported significant gains in FEV1, walking distance and quality of life, along with fewer exacerbations (PMID 30508939). The 2026 prospective study in the Journal of Clinical Medicine found no significant change in FEV1. The two findings are not consistent, and we do not have the data to say which is closer to the truth. For that reason we make no promise of improvement in lung function.
Publications cited on this page
- Prospective study of Broncho Muco Cleaner balloon dilation therapy — Journal of Clinical Medicine, July 2026 · PMID 42513520DOIPubMed recordPMC full text
- Larger follow-up series of 188 patients — Medicine (Baltimore), November 2018 · PMID 30508939PubMed record
The full evidence
The source of every figure on this page, with full publication details and PubMed links, is listed on the clinical evidence page. You will also find the outcomes table and the comparison with other bronchoscopic methods there.
Clinical evidence and publication listHow should the decision be made?
Establish the phenotype: is chronic bronchitis or emphysema dominant? This distinction is made with pulmonary function tests and lung imaging.
Set expectations correctly: the goal is less breathlessness, fewer exacerbations and better quality of life — not a better lung function test result.
Do not abandon core treatment: smoking cessation, medication and pulmonary rehabilitation continue.
The decision belongs to the physician: eligibility is determined only by a pulmonologist's assessment.
Related pages
Ask your questions directly
Contact us for a free preliminary assessment. Whether it suits you is determined by a physician after the necessary tests.
This content is for information only and does not replace a physician's examination. Consult a healthcare provider for diagnosis and treatment.